Non-invasive Assessment of Glymphatic Flow and Neurodegeneration from Wearable Device
Summary
USPTO granted patent US12599332B2 to Applied Cognition, Inc. for a computer-implemented method and system that processes neurophysiological and neurovascular data recorded during sleep from wearable devices to assess glymphatic flow and predict neurodegeneration markers. The patent covers function mapping from the recorded data to target markers including glymphatic flow markers, molecular analysis markers, and neuroimaging markers of neurodegeneration. The patent contains 30 claims.
What changed
USPTO granted patent US12599332B2 to Applied Cognition, Inc. for a computer-implemented method and system for non-invasive assessment of glymphatic flow and neurodegeneration using neurophysiological and neurovascular data from wearable devices. The patent covers function mapping algorithms that output target prediction models for neurodegeneration markers.\n\nThis patent grant establishes intellectual property protection for Applied Cognition's wearable-based neurodegeneration assessment technology. Competitors developing similar wearable neurotechnology for sleep-based glymphatic assessment may need to design around this patent or seek licensing arrangements.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Non-invasive assessment of glymphatic flow and neurodegeneration from a wearable device
Grant US12599332B2 Kind: B2 Apr 14, 2026
Assignee
Applied Cognition, Inc.
Inventors
Paul Dagum, Gregory T. A. Kovacs, Laurent B. Giovangrandi, Carl J. Weber, Joerg C. Student, Nathan Whipple, Jonathan I. Kaplan
Abstract
A computer-implemented method and system includes accessing neurophysiological and neurovascular data recorded during sleep. A function mapping is executed from said neurophysiological and neurovascular data to a target that is one of a glymphatic flow marker, a molecular analysis marker of neurodegeneration, or a neuroimaging marker of neurodegeneration. A target prediction model is output based on the function mapping. The target prediction model can receive new neurophysiological and neurovascular data and output a predicted marker of neurodegeneration.
CPC Classifications
A61B 5/4088 A61B 5/0006 A61B 5/0205 A61B 5/372 A61B 5/418 A61B 5/6817 A61B 5/7275 A61B 2562/166 A61B 5/4806 A61B 5/4064 G01R 33/5601 G01R 33/56341
Filing Date
2024-04-15
Application No.
18636234
Claims
30
Related changes
Get daily alerts for USPTO Patent Grants - Diagnosis & Surgery (A61B)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Diagnosis & Surgery (A61B) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.